

# 2026

Laboratory of Translational Oncology, University of Crete, Greece

Under the auspices of the Medical School of University of Crete

## MOLECULAR ANALYSIS FOR PRECISION CANCER THERAPY

Assays - Challenges in  
analysis, reporting and  
interpretation of results-  
Integration in Clinical practice

Meeting at  
Postgraduate Auditorium,  
School of Medicine,  
University of Crete

27-28 February 2026


Anticancer Research Support Association (ARSA)

INFO: <https://oncopog.com>

CONTACT: [protypoevents@gmail.com](mailto:protypoevents@gmail.com)

# WHO WE ARE

HOST



**Dimitrios Mavroudis**  
Professor of Medical Oncology  
Department of Medical Oncology  
University General Hospital of Heraklion  
Laboratory of Translational Oncology,  
School of Medicine,  
University of Crete

**Sofia Agelaki**  
Professor of Medical Oncology  
Department of Medical Oncology  
University General Hospital of Heraklion  
Laboratory of Translational Oncology,  
School of Medicine,  
University of Crete

**John Souglakos**  
Professor of Medical Oncology  
Department of Medical Oncology  
University General Hospital of Heraklion  
Laboratory of Translational Oncology,  
School of Medicine,  
University of Crete


**Post-doctoral Researchers**  
Maria Mortoglou, MSc, PhD  
Maria Papadaki, PhD  
Eleni Politaki, MSc, PhD  
Maria Sfakianaki, PhD

**Research Assistant**  
Despoina Aggouraki, MSc

**Technicians**  
Georgia Saloustrou

**PhD students**  
Chara Koutoulaki, BSc  
Konstantinos Vogiatzoglou, MSc  
Sofia Chatziavraam, BSc

ORGANISER



# WELCOME ADDRESS

Dear colleagues,

It is a great pleasure to welcome you to the 3rd Molecular Analysis for Precision Cancer Therapy Workshop 2026, organized by the Laboratory of Translational Oncology in collaboration with the Department of Medical Oncology at the University General Hospital of Heraklion.

Precision oncology is rapidly evolving, transforming cancer care from molecular discovery to real-world clinical decision-making. Advances in cancer genomics, epigenomics, liquid biopsy technologies, and integrative data analysis have reshaped our understanding of tumor biology and enabled the identification of actionable biomarkers, tumor-agnostic targets, and innovative therapeutic strategies such as antibody–drug conjugates and minimal residual disease monitoring. In this rapidly changing landscape, cancer management today increasingly relies on accurate molecular profiling, robust analytical workflows, and multidisciplinary interpretation.

This year's workshop is designed to address these challenges by bridging molecular science with clinical practice. Through a comprehensive program that comprises sequencing technologies, interpretation of genomic reports, epigenetic mechanisms, emerging targeted therapies, liquid biopsy applications, and Molecular Tumor Board discussions, the workshop aims to equip early-career oncologists, researchers, and healthcare professionals with the essential knowledge and practical insights required for precision cancer care in 2026.

We anticipate a highly interactive meeting that will foster critical discussion, hands-on understanding of laboratory and analytical processes, and collaboration across disciplines. We look forward to welcoming you and to working together toward advancing patient-centered precision oncology.

**Prof. Sofia Agelaki**

**Prof. Dimitrios Mavroudis**

**MOLECULAR  
ANALYSIS**  
FOR PRECISION  
CANCER THERAPY

# LABORATORY OF TRANSLATIONAL ONCOLOGY

The Laboratory of Translational Oncology, has been established at the Faculty of Medicine, University of Crete (UoC) and operates in close collaboration with the Department of Medical Oncology, University General Hospital of Heraklion to bridge translational and clinical research activities.

The Department of Medical Oncology (DMO) is the reference center for patients with cancer for the area of Crete, Greece, since it receives approximately 1.000 new cancer patients per year and follows more than 10.000 cancer patients. The mission of the DMO is to provide clinical care to patients with cancer, to perform basic and clinical research, and to provide education and training to the next generation of scientists who are focused on the biology and treatment of cancer.

In the Laboratory of Translational Oncology (LTO) clinical and translational researchers and clinical oncologists interact, collaborate, and pool their expertise towards advancing cancer care and research. The Laboratory has all the equipment needed for its research activities aiming for a better understanding of the molecular mechanisms underlying cancer development and progression and for the development of novel issue and liquid biopsy-based prognostic and predictive biomarkers to advance precision medicine in Oncology.

LTO is part of the Hellenic Molecular Oncology Network (EDIMO), with the aim to enhance the prevention, diagnosis, and treatment of cancer patients and to develop new techniques for personalizing health care services offered to cancer patients.

LTO has actively participated in several EU-funded projects, as well as in National funded research projects.



## GENERAL INFORMATION

### Workshop Venue

School of Medicine, University of Crete  
Laboratory of Translational Oncology  
Postgraduate Auditorium

Organised by Anticancer Research Support Association (ARSA), 27-28 February 2026

### TARGET AUDIENCE

Oncology Fellows/Residents  
Researchers and others involved in the care of cancer patients.



### CME Accreditation

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 16 European CME credits (ECMEC®s).

EACCME  
European Accreditation  
Council for Continuing  
Medical Education



MOLECULAR  
ANALYSIS  
FOR PRECISION  
CANCER THERAPY

# LIST OF PARTICIPANTS

<b>Adamaki M.</b>	Molecular Biologist (PhD), Instructor & Academic Advisor in the Department of Biomedical Sciences, New York College Athens, and Independent Scientific Associate of the Institute of Chemical Biology, National Hellenic Research Foundation
<b>Agelaki S.</b>	Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Aggouraki D.</b>	MSc, Research Assistant, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Anagnostopoulos A.</b>	Assistant Professor of Interventional Pulmonology, "Sotiria" Hospital
<b>Baritaki S.</b>	Associate Professor of Experimental Oncology, School of Medicine, University of Crete
<b>Bompolaki I.</b>	Medical Oncologist, General Hospital of Chania "Agios Georgios"
<b>Boukouris A.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
<b>Chatzaki E.</b>	Professor, Laboratory of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Greece
<b>Chatziavraam M.</b>	PhD student, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Chatzopoulos P.</b>	Oncology Resident, University Hospital of Alexandroupolis
<b>Chondrozoumaki M.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
<b>Christakou E.</b>	Medical Oncologist, Hellenic Anticancer Hospital "Metaxa"
<b>De Bree E.</b>	Professor of General Surgery and Surgical Oncology, School of Medicine, University of Crete, and Head of the Surgical Oncology Clinic, University Hospital of Heraklion
<b>Dedes N.</b>	Oncology Resident, "Alexandra" General Hospital of Athens
<b>Dimaras P.</b>	MD, MSc, PhD, Medical Oncologist
<b>Dimovelis G.</b>	MD, MSc, Medical Oncology Resident, "Agios Sawvas" Anticancer Oncology Hospital
<b>Drositis I.</b>	Medical Oncologist, General Hospital of Heraklion "Venizeleio"
<b>Evangelou G.</b>	Medical Oncologist, Clinical Associate, National and Kapodistrian University of Athens, "Sotiria" Hospital
<b>Fostira F.</b>	PhD, Clinical Laboratory Geneticist, Faculty Researcher NCSR "Demokritos"
<b>Georgiadou M.</b>	MD, PhD, Medical Oncologist, University General Hospital of Heraklion
<b>Gkoura S.</b>	Medical Oncologist, University General Hospital of Heraklion
<b>Goulielmaki M.</b>	Biologist, Postdoctoral Researcher, Center for Cancer Immunology and Immunotherapy, "Agios Sawvas" Anticancer Oncology Hospital
<b>Kalapanida D.</b>	MD, PhD, Medical Oncologist, 3rd Medical Oncology Clinic, "Hygeia" Hospital
<b>Kalbakis K.</b>	Medical Oncologist, University General Hospital of Heraklion
<b>Kamaratou M.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
<b>Karachaliou A.</b>	Oncology Resident, 3rd University Department of Internal Medicine, "Sotiria" Hospital
<b>Karachaliou N.</b>	Medical Director, Global Clinical Development, Merck KGaA, Darmstadt, Germany
<b>Karadaglis P.</b>	Medical Oncologist, "Agios Loukas" Clinic
<b>Katsika L.</b>	Oncology Resident, "Theageneio" Hospital
<b>Kontopodis E.</b>	Medical Oncologist, General Hospital of Heraklion "Venizeleio"
<b>Korkovelou A.</b>	Oncology Resident, "Sotiria" Hospital
<b>Koronakis G.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
<b>Koukouraki S.</b>	Professor of Nuclear Medicine, University of Crete, Director of the Department of Nuclear Medicine, University Hospital of Heraklion
<b>Koutoulaki C.</b>	PhD student, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Koutsopoulos A.</b>	Professor of Pathology, School of Medicine, University of Crete and University General Hospital of Heraklion
<b>Kyriakidou A.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
<b>Lampri E.</b>	Assistant Professor, Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina
<b>Lani I.</b>	Oncology Resident, "Evaggelismos" Hospital
<b>Latsis T.</b>	Research Scientist, INSERM, U1310, France
<b>Lazaridis G.</b>	Assistant Professor of Medical Oncology, School of Medicine, A.U.Th., Department of Medical Oncology, G.H.Papageorgiou
<b>Liloglou T.</b>	Cancer Biologist, Programme Lead for MCh (Master of Surgery) Programme, Edge Hill University Medical School, UK
<b>Linardaki E.</b>	Post-doctoral Researcher, Diagnostic Genetics & Precision Medicine Unit (DIGENIA), Foundation for Research and Technology - Hellas (FORTH)
<b>Liontos M.</b>	Medical Oncologist, Assistant Professor of Therapeutic Oncology, National and Kapodistrian University of Athens, Oncology Unit, "Alexandra" General Hospital of Athens
<b>Lydaki D.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion

<b>Magklara A.</b>	Professor of Clinical Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina and Biochemistry (Clinical Chemistry) Laboratory, University General Hospital of Ioannina
<b>Mala A.</b>	Medical Oncologist, University General Hospital of Heraklion
<b>Manolakou S.</b>	MD, PharmD, MSc Medical Oncologist, Medical Collaborator Iasis General Clinic Chania, PhD candidate, Translational Oncology Laboratory, Medical Department, University of Crete
<b>Mauri D.</b>	Assistant Professor, Aristotle University of Thessaloniki
<b>Mavroudis D.</b>	Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Michailidou K.</b>	Biologist, MSc, PhD, Diagnostics Manager, AstraZeneca Greece
<b>Michelakis D.</b>	Surgical Oncologist, MD, MSc (Oncology), PhD, FEBS (Surgical Oncology), Assistant Professor of General Surgery and Surgical Oncology, School of Medicine, University of Crete, Surgical Oncology Clinic, University Hospital of Heraklion
<b>Milaki G.</b>	Medical Oncologist, Director of the Oncology Department, Creta Interclinic, HHG
<b>Mortoglou M.</b>	Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Nikiforou A.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
<b>Papadaki M.</b>	Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Papadakis M.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
<b>Papageorgiou F.</b>	Biologist, PhD, Diagnostics Lead Oncology AstraZeneca Greece
<b>Papaioannou A.</b>	Oncology Resident, "Papageorgiou" Hospital
<b>Papavasileiou S.</b>	Oncology Resident, "Theageneio" Hospital
<b>Pistilli B.</b>	Medical Oncologist and Head of Breast Cancer Unit at Gustave Roussy, Scientific Coordinator of OASIS program
<b>Politaki E.</b>	Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Rovithi M.</b>	Medical Oncologist, General Hospital of Agios Nikolaos, Crete
<b>Saloustris E.</b>	Associate Professor, General University Hospital of Larissa
<b>Saloustrou G.</b>	Technician, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Sandberg P.</b>	Oncology Resident, "Agioi Anargyroi" Hospital
<b>Sarantis P.</b>	Postdoctoral Research Fellow, Medical School of Athens and Biomedical Research Foundation of the Academy of Athens
<b>Sarris E.</b>	Medical Oncologist, Consultant, 4th Oncology Department & Comprehensive Clinical Trials Center, Metropolitan Hospital
<b>Sfakianaki M.</b>	Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Souglakos J.</b>	Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Stoupis J.</b>	Medical Oncologist, General Hospital of Heraklion "Venizeleio"
<b>Svoliantopoulos K.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
<b>Theodoropoulos P.</b>	Professor of Biochemistry, School of Medicine, University of Crete
<b>Thomopoulou K.</b>	MD, MSc, PhD, Medical Oncologist, Hygeia Hospital, Athens
<b>Tikoudi P.</b>	Oncology Resident, "Papageorgiou" Hospital
<b>Tolia M.</b>	Associate Professor of Radiation Oncology, School of Medicine, University of Crete, Director of the Department of Radiation Oncology, University Hospital of Heraklion
<b>Troullinou K.</b>	Oncology Resident, General Hospital of Chania "Agios Georgios"
<b>Tsaknakis G.</b>	Post-doctoral Researcher, Haemopoiesis Research Laboratory, School of Medicine, University of Crete
<b>Tsintarakis A.</b>	Molecular Biologist, MSc, Scientific Associate, Department of Genomics, IATROPOLIS Medical Group
<b>Tzagkaraki E.</b>	Post-doctoral Researcher, DIGENIA, Human Genetics & Precision Medicine, Foundation for Research and Technology - Hellas (FORTH)
<b>Tzimika L.</b>	Oncology Resident, "Theageneio" Hospital
<b>Vardakis N.</b>	Medical Oncologist, University General Hospital of Heraklion
<b>Vathiotis J.</b>	Medical Oncologist, 3rd University Department of Internal Medicine, "Sotiria" Hospital
<b>Vogiatzoglou K.</b>	PhD student, Laboratory of Translational Oncology, School of Medicine, University of Crete
<b>Vorgia E.</b>	Post-doctoral Researcher, DIGENIA, Human Genetics & Precision Medicine, Foundation for Research and Technology - Hellas (FORTH)
<b>Yerolatsite M.</b>	Oncology Resident, University Hospital of Ioannina
<b>Zarkavelis G.</b>	Medical Oncologist, University Hospital of Ioannina
<b>Zazas E.</b>	Oncology Resident, "Attikon" Hospital
<b>Zioudas C.</b>	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
<b>Zoumpourlis V.</b>	Research Director, National Hellenic Research Foundation (NHRF)

Meeting at Postgraduate Auditorium,  
School of Medicine, University of Crete

08:45 - 09:00 Welcome Note

09:00 - 09:30 **The Genetic landscape of cancer** D. Mavroudis,  
P. Theodoropoulos

- A brief history of cancer genetics V. Zoumpourlis

09:30 - 10:45 **Sequencing approaches for identifying targetable  
molecular alterations in cancer** E. Linardaki, A. Magklara,  
G. Zarkavelis

- Shaping precision medicine: the journey of sequencing technologies across human solid tumors G. Tsaknakis
  - Overview of DNA and RNA NGS workflow E. Vorgia
  - NGS testing in the clinical setting F. Papageorgiou
- Discussion

day 1 Friday

February/2026



10:45 - 12:00 **How to read and interpret clinically oriented genomics reports** E. Linardaki, G. Zarkavelis

- Interpreting sequencing results: biological and clinical classification of genetic variants E. Tzagkaraki
  - Functional and clinical annotation of NGS data E. Lampri
  - Structure of a clinical genomics report E. Linardaki
  - Next-generation sequencing in oncology: navigating the ESMO guidelines M. Rovithi
- Discussion

12:00 - 12:30 **Coffee Break**

12:30 - 13:00 **Lecture** S. Agelaki, M. Lontos

- The benefits of comprehensive genomic profiling for patients with cancer J. Vathiotis

13:00 - 14:30 **Beyond the genome: the epigenetic story of cancer**

S. Baritaki, E. Chatzaki, V. Zoumpourlis, P. Theodoropoulos

- The epigenome and its elements T. Liloglou
  - Integrating epigenomics into the molecular characterization of cancer A. Tsintarakis
  - The role of the epigenome in tumour heterogeneity and treatment resistance M. Goulielmaki
  - Epigenetic therapy in cancer M. Adamaki
  - iPSCs in cancer therapy T. Latsis
- Discussion

14:30 - 16:00 **Lunch break**

Beyond the Genome:  
challenges and future perspectives



- 16:00-17:00 **From evidence to clinical practice** I. Drositis, P. Karadaglis, J. Vathiotis
- 16:00 - 16:15 • Are ADCs new tumour-agnostic therapeutics: the HER2 paradigm P. Dimaras
- 16:15 - 16:30 • Molecular classification and first-line treatment of endometrial cancer A. Kyriakidou
- 16:30 - 16:45 • TROP2: biological evolution and therapeutic exploitation G. Koronakis
- 16:45 - 17:00 Discussion

## Workshop

- 17:00-19:30 **Laboratory workflow and analytical processes**
- 17:00-17:30 **Introduction**
- 17:30-18:10 **CTC isolation and analysis:** S. Chatziavraam, M. Papadaki, E. Politaki, G. Saloustrou, K. Vogiatzoglou
- 17:30 - 17:45 • CTC isolation: parsortix, ficoll
- 17:45 - 18:00 • CTC phenotypic analysis
- 18:00 - 18:10 Discussion
- 18:10-19:00 **Sequencing workflow:** D. Aggouraki, M. Sfakianaki, K. Vogiatzoglou
- 18:10 - 18:20 • Microdissection
- 18:20 - 18:30 • DNA extraction
- 18:30 - 18:40 • Sequencing
- 18:40 - 18:50 • Data analysis
- 18:50 - 19:00 Discussion
- 19:00-19:30 **PCR-based techniques:** C. Koutoulaki, M. Mortoglou, M. Sfakianaki
- 19:00 - 19:10 • Digital droplet PCR
- 19:10 - 19:20 • Idylla platform
- 19:20 - 19:30 Discussion

**Trainers:** D. Aggouraki, S. Chatziavraam, C. Koutoulaki, M. Mortoglou, M. Papadaki, E. Politaki, G. Saloustrou, M. Sfakianaki, K. Vogiatzoglou

**Trainees:** A. Boukouris, P. Chatzopoulos, M. Chondrozoumaki, N. Dedes, G. Dimovelis, M. Kamaratou, A. Karachaliou, L. Katsika, A. Korkovelou, G. Koronakis, A. Kyriakidou, I. Lani, D. Lydaki, A. Nikiforou, M. Papadakis, A. Papaioannou, S. Papavasileiou, P. Sandberg, K. Svliantopoulos, P. Tikoudi, K. Troullinou, L. Tzimika, M. Yerolatsite, E. Zazas, C. Zioudas



- 09:00 - 10:00 **Lung neuroendocrine tumors** S. Koukouraki, G. Evangelou, K. Kalbakis
- 09:00 - 09:15 • Optimal management and follow-up of early stage lung carcinoids A. Anagnostopoulos
- 09:15 - 09:30 • Systemic therapy for advanced disease G. Evangelou
- 09:30 - 09:45 • Peptide receptor radionuclide therapy (PRRT) S. Koukouraki
- 09:45 - 10:00 Discussion
- 10:00 - 11:00 **Targeting c-MET alterations in cancer** G. Evangelou, D. Mauri
- 10:00 - 10:15 • Testing for c-MET alterations N. Karachaliou
- 10:15 - 10:30 • Targeting c-MET in lung cancer E. Kontopodis
- 10:30 - 10:45 • Targeting c-MET in gastrointestinal cancer N. Vardakis
- 10:45 - 11:00 Discussion
- 11:00 - 12:00 **Molecular testing to transform patient outcomes** I. Bompolaki, K. Kalbakis
- 11:00 - 11:15 • Timing, prognostic and therapeutic testing in prostate cancer J. Stoupis
- 11:15 - 11:30 • Timing, prognostic and therapeutic testing in HR+, HER2- metastatic breast cancer A. Mala
- 11:30 - 11:45 • The clinical impact of comprehensive biomarker testing in early-stage NSCLC E. Sarris
- 11:45 - 12:00 Discussion

day 2 Saturday

February/2026

# 28

# Molecular analysis for precision cancer therapy

- 12:00 - 12:30 **Coffee Break**
- 12:30 - 14:00 **Advances in precision targeting** G. Milaki, G. Lazaridis
- 12:30 - 12:45 • Targeting EGFR mutant NSCLC S. Gkoura
  - 12:45 - 13:00 • Rare targets in NSCLC: HER2, EGFR exon 20, RET, ROS1 E. Christakou
  - 13:00 - 13:15 • What's new in KRAS targeting in cancer P. Karadaglis
  - 13:15 - 13:30 • IDH mutations: the target, the testing and patient management D. Kalapanida
  - 13:30 - 13:45 • ESR1 mutated breast cancer: overcoming endocrine resistance I. Bompolaki
  - 13:45 - 14:00 Discussion
- 14:00 - 14:30 **Lecture** D. Mavroudis, E. Saloustros
- Unlocking the potential of antibody–drug conjugates: The OASIS perspective B. Pistilli
- 14:30 - 16:00 **Lunch break**
- 16:00 - 17:30 **Advances in liquid biopsy: from exploration to practical application** S. Agelaki, D. Mauri
- 16:00 - 16:15 • Circulating tumor cells and clinical application M. Papadaki
  - 16:15 - 16:30 • Clinical applications of ctDNA in breast cancer K. Thomopoulou
  - 16:30 - 16:45 • ctDNA-guided adjuvant chemotherapy in colon cancer: is it ready to use? S. Manolakou
  - 16:45 - 17:00 • Ultrasensitive MRD monitoring K. Michaelidou
  - 17:00 - 17:15 • The value of extracellular vesicles for cancer profiling and monitoring P. Sarantis
  - 17:15 - 17:30 • Systemic anti-tumour immunity in clinical outcomes A. Boukouris
- 17:30 - 17:45 **Break**
- 17:45 - 20:30 **Molecular tumour board in clinical practice** F. Fostira, D. Mavroudis, E. Saloustros, J. Souglakos
- 17:45 - 18:00 • ESMO precision oncology working group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice M. Georgiadou
  - 18:00 - 18:15 • Isolated central nervous system metastasis following hysterectomy due to POLE-mutated endometrial carcinoma N. Dedes
  - 18:15 - 18:30 • Clinical benefit of first line therapy in BRAF mutant colorectal cancer I. Lani

- 18:30 - 18:45 • Dealing with the uncommon P. Chatzopoulos
- 18:45 - 19:00 • EGFR-mutant metastatic NSCLC M. Yerolatsite
- 19:00 - 19:15 • ALK positive - NSCLC lung A. Papaioannou
- 19:15 - 19:30 • Differential Diagnosis of Primary Versus Metastatic Disease: The Role of Molecular Profiling E. Zazas
- 19:30 - 19:45 • EGFR-Mutated Non–Small Cell Lung Cancer with Disease Progression on First-Line Therapy M. Papadakis
- 19:45 - 20:00 • Managing Multi-Driver NSCLC: An MDT Approach to Concurrent EGFR and MET Genomic Alterations A. Korkovelou
- 20:00 - 20:30 Discussion / Conclusions F. Fostira, A. Magklara, M. Tolia, E. Tzagkaraki, A. Koutsopoulos, D. Mavroudis, D. Michelakis



Beyond the  
Genome:  
From evidence  
to clinical  
practice

